OpenAI has launched a comprehensive biodefense program, highlighted by a $30 million seed investment in Valthos, an AI startup specializing in the rapid detection of biological threats. This initiative aims to enhance global pandemic preparedness through advanced AI technologies. Valthos, which emerged from stealth in October 2025, focuses on real-time identification of biological threats and developing adaptive countermeasures. In addition to the investment, OpenAI has introduced GPT-Rosalind, a specialized AI model for drug discovery and biological research. The company is also collaborating with Los Alamos National Laboratory to ensure the safe deployment of AI in bioscience environments. These efforts are part of OpenAI's broader strategy to build infrastructure for biosecurity before potential crises arise, marking a significant step in the intersection of AI and biodefense.